Moreover, KRAS mutations are emerging as major players in a variety of non-neoplastic malformative vascular lesions and benign tumors including subsets of capillary hemangioma [29], non-ossifying fibroma of bone [30], brown tumor of hyperparathyroidism [31] and others. This evidence concerns the gene KRAS and hyperparathyroidism.